Biosimilar Inflectra Matches Remicade as Crohn’s Treatment, Trial Results Show

Biosimilar Inflectra Matches Remicade as Crohn’s Treatment, Trial Results Show
The biosimilar therapy Inflectra (infliximab CT-P13) is as good a treatment as Remicade (infliximab) for those with moderate-to-severe Crohn’s disease (CD), according to the results of a clinical trial. Pfizer and Celltrion Healthcare, which developed Inflectra, presented the results at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO). Two hundred fourteen patients with Crohn’s participated in the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *